ERBB2 and breast carcinoma: In spite of the fact that the mechanism is not fully defined, the lessons learned from Cyclin D1 and Cdk4 null mouse models have important implications with respect to therapeutic modalities that might be effective in the treatment of breast cancers that are HER2-positive.